IRTA-CReSA joins in the project TRANSVAC2 for the development of a European vaccine research infrastructure
The TRANSVAC2 (European Vaccine Research and Development Infrastructure) held its Kick Off Meeting in Heidelberg, Germany, on May 30-31, 2017.
The TRANSVAC2 consortium comprises a comprehensive collection of leading European institutions that propose to further advance with the previous initiative towards the establishment of a fully operational and sustainable European vaccine R&D infrastructure. TRANSVAC2 will support innovation for both prophylactic and therapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimizing the knowledge and expertise gained during the development of both human and animal vaccines. This will be achieved by bridging the translational gap in biomedical research, and by supporting cooperation between public vaccine R&D institutions of excellence, related initiatives and networks in Europe, and industrial partners. TRANSVAC2 is a consortium with 26 European partners, including leading human and veterinary research institutions, non-governmental organizations, regulatory agencies, and expert academic groups. One of the partners of this consortium is CReSA (Centre de Recerca en Sanitat Animal), a center from IRTA (Institut de Recerca i Tecnologia Agroalimentàries), and Dr. Joaquim Segalés, one of the researchers of the project, attended the Meeting.